Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Paternally-expressed gene 3 protein (PEG3) is a large, multifunctional, paternally imprinted transcription factor encoded by the PEG3 gene, which is expressed exclusively from the paternal allele[3][1][6]. It is characterized by twelve C2H2-type Krüppel zinc finger domains and an N-terminal SCAN domain that facilitates homo- and heterodimerization, essential for its combinatorial regulation of target genes[1][7]. PEG3 regulates gene expression by binding DNA in a sequence-specific manner and primarily functions as a transcriptional repressor for its downstream genes, including other imprinted loci[5][1]. PEG3 participates in diverse biological processes such as fetal growth control, maternal and nurturing behavior, autophagy, apoptosis via p53, repression of Wnt/β-catenin signaling, regulation of mitochondrial genes, and metabolic reprogramming[2][5][4]. It is a critical tumor suppressor frequently dysregulated in cancer through epigenetic silencing (hypermethylation), and its loss is implicated in multiple human malignancies[2][4][6]. PEG3 is also recognized as a marker of competent self-renewing adult stem cells, and its proper regulation is required for cell differentiation and developmental processes[4]. PEG3 can interact with proteins such as SIAH1, TRAF2, and β-catenin, modulating key signaling pathways in cell survival, death, and metabolism[1][3]. Despite its importance in development and disease, PEG3 is not currently considered a direct pharmaceutical target, and no drugs are known to act on PEG3 directly. Its epigenetic status and loss of expression provide potentially valuable biomarkers for cancer prognosis and patient selection[2][6]. No specific safety concerns exist tied to direct targeting, though dysregulation of PEG3 or therapies impacting imprinting could have pleiotropic developmental and oncogenic risks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Paternally-expressed gene 3 protein (PEG3).